Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Gastrointestinal Stromal Tumors 2Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma 1Burkitt Lymphoma 1

Interventions

Doxorubicin 25Radiotherapy 16Ifosfamide 14Trabectedin 10pazopanib 6ribociclib 5pembrolizumab 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5palbociclib 4Radiation 4Docetaxel 4Chemotherapy, Adjuvant 4selinexor 3liposomal doxorubicin 3eribulin 3abemaciclib 3X-Rays 3Vincristine 3Neoadjuvant Therapy 3Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3toripalimab 2temsirolimus 2romidepsin 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × tanespimycin × Sarcoma × Clear all
NCT00969917 2015-04-14

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Infinity Pharmaceuticals, Inc.

Phase 2 Withdrawn
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡